Chemoimmunotherapy: An immunotherapeutic approach to metastatic pancreatic cancer having failed all forms of chemotherapy has been developed and has finished phase II trials. The results are produced by antibody Neo 102 targeting a post translational modification of MUC5ac which is an oncofetal protein expressing mucin production in the GI tract of the fetus. The mAb targets the protein by ADCC of better than 70% .
Answered 2/27/2016
1.6k views
The future is coming: Nanoparticle therapy, biologic therapies, and vaccine trials are coming up in the next few years for pancreatic cancer. A lot of work still to be done!
Answered 2/27/2016
1.6k views
7 doctors weighed in across 2 answers
14 doctors weighed in across 4 answers
3 doctors weighed in across 2 answers
A doctor has provided 1 answer
A doctor has provided 1 answer
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question